HK Stock Market Move | HBM HOLDINGS-B(02142)rose by over 12%, announces HK$40 million buyback plan this month, previously reached development cooperation with Candid.

HBM HOLDINGS-B(02142) rose by more than 12%, rising by 12.05% to 2.51 Hong Kong dollars as of the time the article was written, with a turnover of 11.726 million Hong Kong dollars. On the news front, on January 2nd, Hepburn Pharmaceuticals announced that it intends to repurchase shares worth no more than 40 million Hong Kong dollars on the open market, based on the repurchase authorization. On January 8, 2025, the company repurchased 250,000 shares for 560,000 Hong Kong dollars. In addition, Hepburn Pharmaceuticals recently announced that its wholly-owned subsidiary, Nona Bio, has reached a research cooperation and licensing agreement with Candid on the development of the next generation T-cell connector. According to the terms of the agreement, Nona Bio has the right to receive upfront and potential milestone payments totaling up to 320 million US dollars. Candid will be responsible for all subsequent development work on the product.